Blueprint Medicines (BPMC) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Blueprint Medicines Revenue Highlights

Latest Revenue (Y)

$508.82M

Latest Revenue (Q)

$128.18M

Main Segment (Y)

Collaboration and License

Main Geography (Y)

UNITED STATES

Blueprint Medicines Revenue by Period

Blueprint Medicines Revenue by Year

Date	Revenue	Change
2024-12-31	$508.82M	104.04%
2023-12-31	$249.38M	22.22%
2022-12-31	$204.04M	13.30%
2021-12-31	$180.08M	-77.31%
2020-12-31	$793.74M	1093.37%
2019-12-31	$66.51M	49.39%
2018-12-31	$44.52M	107.79%
2017-12-31	$21.43M	-22.85%
2016-12-31	$27.77M	143.61%
2015-12-31	$11.40M	100.00%
2014-12-31	-	100.00%
2013-12-31	-	-

Blueprint Medicines generated $508.82M in revenue during NA 2024, up 104.04% compared to the previous quarter, and up 765.01% compared to the same period a year ago.

Blueprint Medicines Revenue by Quarter

Date	Revenue	Change
2024-09-30	$128.18M	-7.22%
2024-06-30	$138.16M	43.74%
2024-03-31	$96.12M	33.57%
2023-12-31	$71.96M	27.21%
2023-09-30	$56.57M	-1.74%
2023-06-30	$57.57M	-9.03%
2023-03-31	$63.29M	63.19%
2022-12-31	$38.78M	-41.22%
2022-09-30	$65.98M	80.53%
2022-06-30	$36.55M	-41.74%
2022-03-31	$62.73M	-41.38%
2021-12-31	$107.02M	342.46%
2021-09-30	$24.19M	-11.38%
2021-06-30	$27.30M	26.51%
2021-03-31	$21.58M	-36.74%
2020-12-31	$34.11M	-95.42%
2020-09-30	$745.12M	8831.06%
2020-06-30	$8.34M	35.28%
2020-03-31	$6.17M	-88.03%
2019-12-31	$51.53M	463.88%
2019-09-30	$9.14M	78.85%
2019-06-30	$5.11M	600.00%
2019-03-31	$730.00K	-29.33%
2018-12-31	$1.03M	-5.66%
2018-09-30	$1.09M	-97.36%
2018-06-30	$41.44M	4243.71%
2018-03-31	$954.00K	-41.40%
2017-12-31	$1.63M	-79.82%
2017-09-30	$8.07M	36.98%
2017-06-30	$5.89M	0.86%
2017-03-31	$5.84M	-24.07%
2016-12-31	$7.69M	24.85%
2016-09-30	$6.16M	-12.81%
2016-06-30	$7.07M	3.05%
2016-03-31	$6.86M	47.92%
2015-12-31	$4.63M	35.29%
2015-09-30	$3.43M	27.50%
2015-06-30	$2.69M	312.12%
2015-03-31	$652.00K	100.00%
2014-12-31	-	100.00%
2014-09-30	-	100.00%
2014-06-30	-	100.00%
2014-03-31	-	-

Blueprint Medicines generated $128.18M in revenue during Q3 2024, up -7.22% compared to the previous quarter, and up 222.66% compared to the same period a year ago.

Blueprint Medicines Revenue Breakdown

Blueprint Medicines Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Collaboration revenue	$3.30M	-	-	-	-
Collaboration and License	$24.30M	-	-	-	-
Royalty	$180.00K	-	-	-	-
AYVAKIT and AYVAKYT	-	$204.21M	$52.98M	-	-
Product	-	$204.21M	$110.99M	$22.13M	-
Product revenue, net	-	-	-	$57.69M	-
GAVRETO	-	-	-	$4.71M	-
Collaboration	-	-	-	-	$771.60M

Blueprint Medicines's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration and License (87.46%), Collaboration revenue (11.89%), and Royalty (0.65%).

Quarterly Revenue by Product

Product/Service	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20
Royalty	-	$198.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration revenue	$1.37M	$1.94M	$15.86M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Collaboration and License	-	$27.63M	$24.04M	$3.59M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Product	-	$128.18M	$114.11M	$125.26M	$39.88M	$39.07M	$30.06M	$8.96M	$6.69M	$6.31M	$5.68M	$3.46M	-	-	-	-	-	-	-
AYVAKIT and AYVAKYT	-	-	-	-	$134.97M	$34.31M	$34.93M	$30.06M	$28.63M	$28.45M	$23.84M	$20.03M	$17.27M	-	-	-	-	-	-
GAVRETO	-	-	-	-	-	$5.57M	$4.14M	-	$4.71M	-	-	-	-	-	-	-	-	-	-
Product revenue, net	-	-	-	-	-	-	-	-	$28.63M	$28.45M	$23.84M	$20.03M	$17.27M	$11.43M	-	-	-	-	-
Collaboration	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$12.62M	$27.42M	$738.81M	$2.66M	$2.71M

Blueprint Medicines's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: Collaboration revenue (100.00%).

Blueprint Medicines Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22
Non-US	$57.11M	$22.24M	$13.77M
UNITED STATES	$421.84M	$181.97M	$97.23M

Blueprint Medicines's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (88.08%), and Non-US (11.92%).

Quarterly Revenue by Country

Country	Dec 24	Sep 24	Jun 24	Mar 24
Non-US	$20.02M	$15.05M	$12.65M	$9.39M
UNITED STATES	$124.11M	$113.13M	$101.46M	$83.14M

Blueprint Medicines's latest quarterly revenue breakdown by geography, as of Dec 24: UNITED STATES (86.11%), and Non-US (13.89%).

Blueprint Medicines Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
PTCT	PTC Therapeutics	$806.78M	$135.42M
BPMC	Blueprint Medicines	$508.82M	$128.18M
KRYS	Krystal Biotech	$290.51M	$83.84M
MDGL	Madrigal Pharmaceuticals	$180.13M	$62.17M
DAWN	Day One Biopharmaceuticals	$131.16M	$20.07M
AMLX	Amylyx Pharmaceuticals	$87.37M	$416.00K
XFOR	X4 Pharmaceuticals	$2.56M	$560.00K
ABOS	Acumen Pharmaceuticals	-	-
INZY	Inozyme Pharma	-	-
TERN	Terns Pharmaceuticals	-	-
MREO	Mereo BioPharma Group	-	-

BPMC Revenue FAQ

What is Blueprint Medicines’s yearly revenue?

Blueprint Medicines's yearly revenue for 2024 was $508.82M, representing an increase of 104.04% compared to 2023. The company's yearly revenue for 2023 was $249.38M, representing an increase of 22.22% compared to 2022. BPMC's yearly revenue for 2022 was $204.04M, representing an increase of 13.30% compared to 2021.

What is Blueprint Medicines’s quarterly revenue?

Blueprint Medicines's quarterly revenue for Q3 2024 was $128.18M, a -7.22% decrease from the previous quarter (Q2 2024), and a 126.61% increase year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $138.16M, a 43.74% increase from the previous quarter (Q1 2024), and a 139.98% increase year-over-year (Q2 2023). BPMC's quarterly revenue for Q1 2024 was $96.12M, a 33.57% increase from the previous quarter (Q4 2023), and a 51.87% increase year-over-year (Q1 2023).

What is Blueprint Medicines’s revenue growth rate?

Blueprint Medicines's revenue growth rate for the last 3 years (2022-2024) was 149.38%, and for the last 5 years (2020-2024) was -35.89%.

What are Blueprint Medicines’s revenue streams?

Blueprint Medicines's revenue streams in c 24 are Collaboration revenue, Collaboration and License, and Royalty. Collaboration revenue generated $3.3M in revenue, accounting 11.89% of the company's total revenue Collaboration and License generated $24.3M in revenue, accounting 87.46% of the company's total revenue Royalty generated $180K in revenue, accounting 0.65% of the company's total revenue

What is Blueprint Medicines’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Blueprint Medicines was Collaboration and License. This segment made a revenue of $24.3M, representing 87.46% of the company's total revenue.